ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 117

Postmenopausal Hormone Therapy and The Risk Of Rheumatoid Arthritis: Results From The Swedish EIRA Study

Cecilia Orellana1, Saedis Saevarsdottir1,2, Lars Klareskog3, Lars Alfredsson1 and Camilla Bengtsson1, 1Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 2Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, 3Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: menopause, rheumatoid arthritis (RA) and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services I

Session Type: Abstract Submissions (ACR)

Background/Purpose: The importance of hormonal/reproductive factors has been hypothesized to contribute to the risk of Rheumatoid arthritis (RA), but the literature is somewhat contradictory. The use of postmenopausal hormone (PMH) has previously been observed to provide increased [1], decreased [2], as well as no association [3] with the risk of RA. The aim of the present work was to study the association between the use of PMH and the risk of developing RA in postmenopausal women (aged 50-70), by stratifying the cases according to presence/absence of antibodies to citrullinated peptides (ACPA).

Methods: Data from the Swedish population-based EIRA (Epidemiological Investigation of RA) case-control study was analyzed. In total, 380 incident postmenopausal female cases, aged 50-70 years, and 780 randomly selected controls (matched by age and residential area) were included between 2006-2009. Of the cases, 239 (62.9%) were ACPA-positive. The use of PMH was assessed by means of an identical questionnaire answered by the participating cases and controls. Current and past users of PMH were compared with never users to obtain odds ratios (ORs) with 95% confidence intervals (CI) by means of unconditional logistic regression models.  

Results: A decreased risk of developing ACPA-positive RA was observed among current users compared with never users of PMH (OR 0.5, 95% CI 0.3-0.9). Among past users of PMH no association was found when comparing with never users (OR 1.2, 95% CI 0.8-1.7).  For ACPA-negative RA no association was found among current (OR 1.0, 95% CI 0.6-1.8) or past (OR 1.2, 95% CI 0.8-2.0) users of PMH.

Conclusion: Our results indicate that current use of PMH is associated with a decreased risk of ACPA-positive RA in postmenopausal women aged 50-70, but has no association with the risk of ACPA-negative RA. The striking difference in the results for ACPA-positive and ACPA-negative RA adds further evidence to the notion that RA consists of two different entities with partly different etiology. Further research is needed in order to explore the biological mechanisms behind our findings.

References

1. Merlino LA, Cerhan JR, Criswell LA et al. (2003) Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum 33, 72-82.

2. Vandenbroucke JP, Witteman JC, Valkenburg HA et al. (1986) Noncontraceptive hormones and rheumatoid arthritis in perimenopausal and postmenopausal women. JAMA 255, 1299-1303.

3. Walitt B, Pettinger M, Weinstein A et al. (2008) Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women’s health initiative randomized controlled trials. Arthritis Rheum 59, 302-310.


Disclosure:

C. Orellana,
None;

S. Saevarsdottir,
None;

L. Klareskog,
None;

L. Alfredsson,
None;

C. Bengtsson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/postmenopausal-hormone-therapy-and-the-risk-of-rheumatoid-arthritis-results-from-the-swedish-eira-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology